Bloomberg -- AstraZeneca Plc Chief Executive Officer David Brennan is counting on investors taking the U.K. drugmaker’s dividend and cash returns as sufficient reward while earnings stall over the next four years.
Bloomberg -- AstraZeneca Plc Chief Executive Officer David Brennan is counting on investors taking the U.K. drugmaker’s dividend and cash returns as sufficient reward while earnings stall over the next four years.
